This request for potential future RS doesn’t make sense as of now, with only 6.4 million shares outstanding. It’s for potential future RS, but Tonix would have to get authorization for more common shares as it did in 2024. In case FDA doesn’t approve. Some ridiculous price targets for exercise of options, like the $3.8 billions/share! 3 legged stool. Need FDA approval for commercial use.
Market Data 
Markets 
AI
